Zobrazeno 1 - 10
of 212
pro vyhledávání: '"John Whitesides"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kwan-Ki Hwang, Ashley M Trama, Daniel M Kozink, Xi Chen, Kevin Wiehe, Abby J Cooper, Shi-Mao Xia, Minyue Wang, Dawn J Marshall, John Whitesides, Munir Alam, Georgia D Tomaras, Steven L Allen, Kanti R Rai, Jane McKeating, Rosa Catera, Xiao-Jie Yan, Charles C Chu, Garnett Kelsoe, Hua-Xin Liao, Nicholas Chiorazzi, Barton F Haynes
Publikováno v:
PLoS ONE, Vol 9, Iss 3, p e90725 (2014)
B-cell chronic lymphocytic leukemia (B-CLL) patients expressing unmutated immunoglobulin heavy variable regions (IGHVs) use the IGHV1-69 B cell receptor (BCR) in 25% of cases. Since HIV-1 envelope gp41 antibodies also frequently use IGHV1-69 gene seg
Externí odkaz:
https://doaj.org/article/ca7014c87aff4e82ac23ca58b421f885
Autor:
Anyzeila Diaz, Vincent Badalamenti, Teresa Gasalla, John Whitesides, Stephan Arnold, Cindy McShea, Toufic Fakhoury
Publikováno v:
Epilepsy Research. 141:73-82
Brivaracetam (BRV), a selective, high-affinity ligand for synaptic vesicle protein 2A, is a new antiepileptic drug (AED) approved for monotherapy (in the USA) and adjunctive treatment of focal (partial-onset) seizures in adults, at a dose range of 50
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::922f69034574ac5da0b3a39406a8c20d
https://doi.org/10.1016/j.eplepsyres.2018.02.005
https://doi.org/10.1016/j.eplepsyres.2018.02.005
Publikováno v:
Clinical Pharmacology : Advances and Applications
Brivaracetam (BRV; Briviact) is a new antiepileptic drug (AED) approved for adjunctive treatment of focal (partial-onset) seizures in adults. BRV is a selective, high-affinity ligand for synaptic vesicle 2A (SV2A) with 15- to 30-fold higher affinity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db4bba57764a546b3028def34d3e2f50
https://doi.org/10.2147/cpaa.s114072
https://doi.org/10.2147/cpaa.s114072
Autor:
Lynn Morris, Xi Chen, Munir Alam, Georgia Tomaras, Ruijun Zhang, Dawn J Marshall, Bing Chen, Robert Parks, Andrew Foulger, Frederick Jaeger, Michele Donathan, Mira Bilska, Elin S Gray, Salim S Abdool Karim, Thomas B Kepler, John Whitesides, David Montefiori, M Anthony Moody, Hua-Xin Liao, Barton F Haynes
Publikováno v:
PLoS ONE, Vol 6, Iss 9, p e23532 (2011)
Broadly neutralizing antibodies are not commonly produced in HIV-1 infected individuals nor by experimental HIV-1 vaccines. When these antibodies do occur, it is important to be able to isolate and characterize them to provide clues for vaccine desig
Externí odkaz:
https://doaj.org/article/9d5bc32a5f504e11ae3e54e27a1dc13c
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Rebecca Beale, John Whitesides, Jennifer S. Evans, Manuel Toledo, Sara Steeves, Sami Elmoufti, Simon Borghs, Rebecca Townsend
Publikováno v:
Epilepsy Research. 138:53-61
Antiepileptic drug (AED) retention rates are frequently reported in the literature and used to inform clinical decision-making, but methodological differences in the determination of retention rates make comparisons between trials difficult. Open-lab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9985e41a20e4590ee2ab455a1599cc86
https://doi.org/10.1016/j.eplepsyres.2017.10.008
https://doi.org/10.1016/j.eplepsyres.2017.10.008
Autor:
Sami Elmoufti, Pavel Klein, Ali A. Asadi-Pooya, Anyzeila Diaz, Jimmy Schiemann, John Whitesides, Steve Chung, Michael R. Sperling
Publikováno v:
Epilepsy Research. 131:70-75
Brivaracetam (BRV), a selective, high-affinity ligand for synaptic vesicle protein 2A, is a new antiepileptic drug (AED) for adjunctive treatment of focal (partial-onset) seizures in adults with epilepsy. This post-hoc analysis was conducted to explo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86f0a688fd7d671698f90170b5aa09f6
Publikováno v:
Epilepsy & Behavior. 103:106864
Objective The objective of this analysis was to provide a comprehensive analysis of safety data for adjunctive brivaracetam (BRV), an antiepileptic drug (AED) of the racetam class, for treatment of focal seizures in patients with epilepsy. Methods Da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3759dd4478854db22fc6931a8cf99dd2
https://doi.org/10.1016/j.yebeh.2019.106864
https://doi.org/10.1016/j.yebeh.2019.106864
Autor:
Michael R. Sperling, Pavel Klein, John Whitesides, Jimmy Schiemann, Patrick Kwan, Tracy Stalvey, Wei Liang, Christian Brandt
Publikováno v:
Epilepsia. 56:1890-1898
SummaryObjective Brivaracetam (BRV), a selective and high-affinity synaptic vesicle protein 2A ligand, is in development as adjunctive treatment for partial-onset (focal) seizures (POS). This phase 3 study (N01358; NCT01261325) aimed to confirm the e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ad07cc36306e38deccb2376f016c4c9
https://doi.org/10.1111/epi.13212
https://doi.org/10.1111/epi.13212